DK2114934T3 - Sammensætning og fremgangsmåder til modulering af en kinasekaskade - Google Patents

Sammensætning og fremgangsmåder til modulering af en kinasekaskade Download PDF

Info

Publication number
DK2114934T3
DK2114934T3 DK07863295.7T DK07863295T DK2114934T3 DK 2114934 T3 DK2114934 T3 DK 2114934T3 DK 07863295 T DK07863295 T DK 07863295T DK 2114934 T3 DK2114934 T3 DK 2114934T3
Authority
DK
Denmark
Prior art keywords
compound
compounds
disclosure
kinase
morpholinoethoxy
Prior art date
Application number
DK07863295.7T
Other languages
English (en)
Inventor
Daniel Coughlin
Jeremy A Cody
Jonathan Gale
David G Hangauer
Debasis Patra
Original Assignee
Athenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39232910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2114934(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athenex Inc filed Critical Athenex Inc
Application granted granted Critical
Publication of DK2114934T3 publication Critical patent/DK2114934T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)

Claims (7)

1. Fremgangsmåde til fremstilling af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-A/-benzylacetamid omfattende trinnet med: at omsætte methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat med benzylamin til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-/V-benzylacetamid.
2. Fremgangsmåde ifølge krav 1, hvorved methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat fremstilles ved trinnet med at omdanne 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitril til methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat:
3. Fremgangsmåde ifølge krav 2, hvorved 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitril fremstilles ved trinnet med at omsætte 4-(2-(4-(6-fluorpyridin-3-yl)phenoxy)ethyl)morpholin med acetonitril:
4. Fremgangsmåde ifølge krav 3, hvorved 4-(2-(4-(6-fluorpyridin-3-yl)phenoxy)ethyl)morpholin fremstilles ved trinnet med at koble 4-(2-(4-bromphenoxy)ethyl)morpholin med 6-fluorpyridin-3-yl-3-borsyre.
5. Fremgangsmåde ifølge krav 1 til 4 omfattende følgende trin: (1) at omsætte 4-(2-chlorethyl)morpholin med 4-bromphenol til opnåelse af 4-(2-(4-bromphenoxy)ethyl)morpholin; (2) at koble 4-(2-(4-bromphenoxy)ethyl)morpholin med 6-fluorpyridin-3-yl-3-borsyre til opnåelse af 4-(2-(4-(6-fluorpyridin-3-yl)phenoxy)ethyl)morpholin; (3) at omsætte 4-(2-(4-(6-fluorpyridin-3-yl)phenoxy)ethyl)morpholin med acetonitril til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitril; (4) at omdanne 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitril til methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat; og (5) at omsætte methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat med benzylamin til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-/V-benzylacetamid.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 eller 5, yderligere omfattende at bringe 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-/V-benzylacetamid i kontakt med en saltsyreopløsning til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-A/-benzylacetamiddihydrochlorid.
7. Fremgangsmåde ifølge krav 6 omfattende følgende trin: (1) at omsætte 4-(2-chlorethyl)morpholin med 4-bromphenol til opnåelse af 4-(2-(4-bromphenoxy)ethyl)morpholin; (2) at koble 4-(2-(4-bromphenoxy)ethyl)morpholin med 6-fluorpyridin-3-yl-3-borsyre til opnåelse af 4-(2-(4-(6-fluorpyridin-3-yl)phenoxy)ethyl)morpholin; (3) at omsætte 4-(2-(4-(6-fluorpyridin-3-yl)phenoxy)ethyl)morpholin med ace-tonitril til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitril; (4) at omdanne 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitril til methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat; (5) at omsætte methyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetat med benzylamin til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-/V-benzylacetamid; og (6) at bringe 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-/\/-benzylacetamid i kontakt med en saltsyreopløsning til opnåelse af 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-A/-benzylacetamiddihydrochlorid.
DK07863295.7T 2006-12-28 2007-12-28 Sammensætning og fremgangsmåder til modulering af en kinasekaskade DK2114934T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87776206P 2006-12-28 2006-12-28
PCT/US2007/026457 WO2008082637A1 (en) 2006-12-28 2007-12-28 Composition and methods for modulating a kinase cascade

Publications (1)

Publication Number Publication Date
DK2114934T3 true DK2114934T3 (da) 2016-01-25

Family

ID=39232910

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07863295.7T DK2114934T3 (da) 2006-12-28 2007-12-28 Sammensætning og fremgangsmåder til modulering af en kinasekaskade

Country Status (10)

Country Link
US (1) US7851470B2 (da)
EP (1) EP2114934B1 (da)
JP (4) JP2010514771A (da)
CN (3) CN101616915B (da)
AU (1) AU2007340350B2 (da)
CA (1) CA2673974C (da)
DK (1) DK2114934T3 (da)
ES (1) ES2559687T3 (da)
TW (1) TWI457336B (da)
WO (1) WO2008082637A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5564251B2 (ja) * 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
US20210198202A1 (en) * 2006-12-28 2021-07-01 Athenex, Inc. Compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
WO2008127727A1 (en) * 2007-04-13 2008-10-23 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
AU2014202221B2 (en) * 2007-05-17 2016-06-23 Atnx Spv, Llc Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof
US8124605B2 (en) 2007-07-06 2012-02-28 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
EP2217229B1 (en) 2007-10-20 2020-10-14 Athenex, Inc. Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
CN102627663A (zh) * 2012-03-23 2012-08-08 上海泰坦化学有限公司 含氟吡啶硼酸的制备方法
CA2883144C (en) 2012-08-30 2023-01-17 Kinex Pharmaceuticals, Llc N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein|tyrosine kinase modulators
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
ES2928593T3 (es) 2015-01-19 2022-11-21 Univ Keio Agentes terapéuticos para el deterioro auditivo del oído interno
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
US10058803B2 (en) * 2015-12-18 2018-08-28 Synfuel Americas Corporation Filter assembly and method of use
CN106902358B (zh) 2015-12-21 2020-07-10 广州市香雪制药股份有限公司 口服制剂及其制备方法
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
TWI755418B (zh) 2016-08-12 2022-02-21 美商亞瑟尼克斯公司 聯芳組成物和調控激酶級聯之方法
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
FI3592355T3 (fi) 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN110034895B (zh) 2018-01-12 2020-07-03 电信科学技术研究院有限公司 信息指示、确定方法及装置、计算机存储介质
CN109485599A (zh) * 2019-01-16 2019-03-19 重庆迈德凯医药有限公司 一种Src酪氨酸激酶抑制剂晶型、其制备方法及药物组合物
CN113354575B (zh) * 2021-06-07 2022-09-27 河南应用技术职业学院 一种特班布林的合成方法
EP4302831B1 (en) 2022-07-04 2025-08-27 Trifarma S.p.A. Process for synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
CN115073362A (zh) * 2022-08-04 2022-09-20 重庆迈德凯医药有限公司 一种替尼布林的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044222B (it) * 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
US20030130209A1 (en) 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
JP2001023259A (ja) * 1999-07-09 2001-01-26 Sony Corp 光磁気記録媒体およびその製造方法
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
CA2441733A1 (en) 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US20040242572A1 (en) * 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
WO2004056774A2 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
MXPA06003949A (es) 2003-10-07 2006-06-27 Renovis Inc Compuestos amida como ligandos del canal de ion y su uso.
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) * 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
CA2602336A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JP5564251B2 (ja) * 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008144045A1 (en) * 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof

Also Published As

Publication number Publication date
CN101616915A (zh) 2009-12-30
WO2008082637A1 (en) 2008-07-10
HK1136570A1 (zh) 2010-07-02
JP2010514771A (ja) 2010-05-06
CA2673974C (en) 2017-01-17
CN102657656A (zh) 2012-09-12
AU2007340350A1 (en) 2008-07-10
CN104230793A (zh) 2014-12-24
AU2007340350B2 (en) 2014-02-20
US7851470B2 (en) 2010-12-14
JP2015232050A (ja) 2015-12-24
CA2673974A1 (en) 2008-07-10
EP2114934B1 (en) 2015-10-21
CN101616915B (zh) 2014-12-17
AU2007340350A2 (en) 2009-09-17
JP2014037439A (ja) 2014-02-27
JP2016222733A (ja) 2016-12-28
ES2559687T3 (es) 2016-02-15
WO2008082637A9 (en) 2008-09-18
TWI457336B (zh) 2014-10-21
TW200827354A (en) 2008-07-01
JP6022657B2 (ja) 2016-11-09
EP2114934A1 (en) 2009-11-11
US20080221102A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
DK2114934T3 (da) Sammensætning og fremgangsmåder til modulering af en kinasekaskade
US10323001B2 (en) Compositions for modulating a kinase cascade and methods of use thereof
US8293739B2 (en) Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
DK2155681T3 (da) Fremgangsmåde til fremstilling af sammensætninger til modulering af kinasekaskade og fremgangsmåder til anvendelse deraf
US20240343691A1 (en) Compositions for modulating a kinase cascade and methods of use thereof
AU2014200559B2 (en) Composition and Methods for Modulating a Kinase Cascade
AU2014202221B2 (en) Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof
HK1136570B (en) Composition and methods for modulating a kinase cascade
HK1141530B (en) Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
HK1141530A (en) Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof